E75.29
Other sphingolipidosis
Clinical Classification Guidelines
Inclusion Terms
- Farber's syndrome
- Sulfatide lipidosis
Medical Intelligence & Overview
Other sphingolipolipidosis, coded as E75.29 in the ICD-10 classification, is a rare genetic disorder characterized by the abnormal buildup of certain fat substances called sphingolipids in various tissues of the body. This condition falls under the broader category of lysosomal storage disorders, which involve the deficiency of specific enzymes needed to break down lipids. Patients with this condition may experience a range of health issues depending on the severity and the tissues affected. Common forms linked to this group include Farber's syndrome and sulfátide lipidosis, each with distinct features but sharing similar underlying mechanisms.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting enzymes responsible for lipid metabolism Autosomal recessive inheritance pattern, requiring both copies of a gene to be affected Deficiency of specific enzymes involved in sphingolipid breakdown, leading to accumulation
Key Symptoms: Joint pain and swelling, often starting early in life Less muscle tone or muscle weakness Skin nodules and rashes Developmental delays or intellectual disability Loss of hearing or vision in some cases Hepatosplenomegaly (enlarged liver and spleen) In some cases, neurological symptoms such as seizures or movement problems
Diagnostic & Treatment
Diagnosis Path: The diagnosis of other sphingolipolipidosis involves a combination of clinical evaluation, family history assessment, and laboratory tests. Key diagnostic steps include:
Treatment Protocols: Current management of other sphingolipolipidosis is primarily supportive and symptomatic, as there are no known cures. Therapeutic approaches include:
Clinical Advice & FAQs
Billing Guidance
Is E75.29 a billable ICD-10 code?
Yes, E75.29 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E75.29?
Clinical documentation must specify the nature of Other sphingolipidosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference